(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n
\n7. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448111\/ Consultado en junio de 20258. Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Disponible en: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov.<\/p>\n
\n9. Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 1999 May;5(5):945-51 <\/p>\n
\n10. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.<\/p>\n
\n11. Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children’s Oncology Group. J Clin Oncol. 2022 Jul; JCO2102478.<\/p>\n
\n12. Basta NO, Halliday GC, Makin G, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115(9):1048-1057. doi:10.1038\/bjc.2016.302.<\/p>\n
\n13. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.<\/p>\n
\n14. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA, Consultado 04.07.25<\/p>\n
\nLogo — https:\/\/mma.prnewswire.com\/media\/597589\/4648918\/Norgine_Logo.jpg<\/p>\n
View original content:https:\/\/www.prnewswire.com\/news-releases\/swissmedic-aprueba-ifinwil-eflornitina-para-ninos-diagnosticados-con-neuroblastoma-de-alto-riesgo-hrnb-302499276.html<\/p>\n","protected":false},"excerpt":{"rendered":"
(Informaci\u00f3n remitida por la empresa firmante) 7. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448111\/ Consultado en junio de 20258. Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Disponible en: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov. 9. Meyskens […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-62467","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/62467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62467"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/62467\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}